idase/hydrogen peroxide and the signal integrated for 10 s. The light yield is inversely proportional to the concentration of estradiol in the standard or sample.
AddItional Keyphrases: rnonoclona! antibodies . synthesis of isoluminol derivatives nonisotopic immunoassay reference interval
Many methods based upon the principles of radioimmunoassay (RIA) have been applied to the determination of estradiol in peripheral venous plasma from women. In particular, the measurement of this hormone has become a routine procedure for monitoring the treatment of functional infertility (1), predicting ovulation (2) , and managing symptoms associated with the menopause (3) . The increasing availability and usefulness of RIA, however, has raised several problems, including Several homogeneous assays have been based upon the phenomenon of antibody-enhanced luminescence of steroid-isoluminol conjugates (8) (9) (10) (11) and have proved satisfactory with respect to sensitivity and precision. One of the major difficulties, however, has been the presence of nonspecific interference from biological fluids, which necessitated the inclusion of procedures for purifying the samples before the antibody-binding reaction.
More recently, an alternative approach has been developed that involves the use of a solid-phase system for separating the antibody-bound fraction (12) (13) (14) (15) 
Materials and Methods

Materials
Reagents. 
Buffers.
Two buffers were used: a barbital buffer (70 mmol/L, pH 9.6) prepared by dissolving 14.4 g of sodium barbital in 1 L of doubly distilled water, and a phosphate buffer (0.1 mol/L, pH 7.5) prepared by dissolving 2.5 g of sodium dihydrogen orthophosphate ' 2H2O plus 11.9 g of dimdium hydrogen orthophosphate in 1 L of doubly distilled water that contained 1 g of BSA and 9 g of sodium chloride. Microperoxidase was dissolved in phosphate buffer and the stock solution (1 g/L) was stored at 4 #{176}C. The working solution was 20 mg/L (50-fold dilution).
The oxidant solution was prepared by adding 100 iL of hydrogen peroxide to 10 mL of doubly distilled water.
buffer. The mean analytical recovery of tritiated estradiol from 20 samples was 80.9% (SD 2.1%). In practice, however, we applied no correction factor for experimental losses.
Procedures
Preparation of chemiluminescent marker conjugate and immunogen.
(estradiol-6-CMO-ABEI conjugate) was synthesized in two steps:
1. Twenty milligrams of estradiol-6-(O)-carboxymethyl oxime, prepared according to the method of Kohen et al. (16) , was dissolved in 0.5 mL of dry dimethylformamide. After addition of 10 mg of N,N-dicyclohexylcarbodiimide and Nhydroxysuccinimide, the reaction mixture was stirred overnight at room temperature (22 #{176}C ). The urea produced was removed by filtration, and the filtrate, which contained the activated ester, was used without further purification.
2. Ten milligrams
(aminobutyl ethyl isoluminol; ABEl), synthesized according to the procedure described by Schroeder et al. (17) , was dissolved in 0.5 mL of sodium bicarbonate (0.13 molfL) and added to the solution containing the N-hydroxysuccinimide ester of estradiol-6-
oxime. The reaction mixture was stirred at room temperature for 1 h and then acidified to pH 2. The precipitate was filtered and purified by chromatography on thin-layer plates (Silica Gel 60) developed in chloroform! methanol (60/40 by vol). The estradiol-6-CMO-ABEI (R1 0.65) was eluted with methanol. The concentration of the conjugate was determined spectrophotometrically ( = 18 000 at 285 nm). A tentative proposed structure of estradiol-6-CMO-ABE! is shown in Figure 1 .
conjugate was prepared by converting 6 mg of estradiol-6-CMO in the free acid form to the activated N-succinimide ester derivative by the procedure described above. BSA (10 mg) was dissolved in 0.5 mL of sodium bicarbonate (0.13 molfL) and added to 0.5 mL of the dimethylformamide solution containing the activated ester.
The mixture was stirred for 30 mm and dialyzed against diluted sodium bicarbonate (0.1 mol/L) and then distilled water. The product was lyophilized, and we calculated from its ultraviolet spectrum that the immunogen contained an average of 16 steroid residues per mole of BSA.
Preparation
of monoclonal antibodies and attachment to solid phase. Inbred C57BL!6 male mice (two to three months old) were immunized by an intradermal injection of estradiol-6-CMO-BSA (100 g per mouse) incorporated in
Freund's complete adjuvant. The injection was repeated two weeks later and subsequent booster injections (100 zg per 
Calculation of Results and Statistical Analyses
The unknown values were derived from the calibration curves (% B/B0 vs concentration of estradiol, pg per tube) and 
Results
Antibody Characteristics
Preparation of monoclonal antibodies.
The fusion of spleen cells from immunized mice with myeloma cells resulted in the formation of hybrid cells. Extensive growth of hybrid cells was evident
in all wells of the tissue culture plates. Antibodysecreting hybridomas were detected by RIA in the tissueculture media from 2% of the wells; we used dextran-coated charcoal to separate the antibody-bound and free fractions. During subsequent cell culture one hybridoma line survived and was cloned by limiting dilutions. When the hybridomas were injected into the treated mice, tumors formed that secreted high amounts of anti-estradiol antibodies into the ascitic fluid. The usable titres (by vol) for RIA ranged from 1: 15000 to 1:100 000. We selected the one with best avidity and specicity for further study. 
Characterization of antibodies (IgG fraction).
Assay Characteristics
Sensitivity.
The minimum concentration of estradiol that 
<1.95 pg per tube, which is equivalent to <36 pmol/L of plasma.
Accuracy.
Increasing amounts of authentic estradiol were added to plasma from males that had been analyzed previously by RIA; the sample were extracted and re-analyzed by CIA. The results, uncorrected for extraction losses, are shown in Table 2 .
Precision.
An estimate of the within-assay variation was obtained by analyzing 10 replicate samples in duplicate within a single assay. The mean value was 312 (SD 29) pmolfL, giving a CV of 9.4%. The corresponding values for between-assay variation were obtained from the measurement of estradiol in aliquots from the plasma pool used for internal quality control over a period of three months (mean 671 pmol/L, SD 53 pmol/L, CV = 7.9%, n = 6). 
Reference Intervals
The concentrations of plasma estradiol in peripheral plasma collected from 34 women during the early follicular, penovulatory, and luteal phases of the menstrual cycle are shown in Table 3 .
Discussion
In recent years there has been much controversy over the bodies to estradiol-6-CMO-BSA. Experiments on cross reactivity indicate a 50% cross reaction with estriol; indeed, the antibody has been used in the development of an homogeneous CIA for plasma estriol (11) . The justification for the use of this antibody in an assay for estradiol is the relatively low concentrations of estriol in peripheral plasma from nonpregnant women. Other, more specific antibodies are required for application of the method to plasma from men and postmenopausal women, and we are testing for this purpose polyclonal antibodies raised in rabbits.
In the development of all immunoassays, there is the need for well-matched reagents, but this requirement is more apparent with nonisotopically labeled antigens. Further improvements to the reported methodology are also proceeding. For example, the use of etched polystyrene beads as the solid support for the antibodies, for use with glass tubes, will allow for the possibility of extracting true duplicates and evaporating the ether directly from the assay tube.
There is no doubt that CIA has already achieved a status comparable with that of RIA in terms of sensitivity and reli- 
